An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms BRAIN-IP
- 13 Nov 2018 Planned End Date changed from 12 Jan 2021 to 1 Sep 2024.
- 08 Aug 2017 New trial record